PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Guardant Health, Inc.

USPTO PatentsView assignee record - 120 granted patents across 12 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

Explore the portfolio See the ranking
120
Total patents granted
12
CPC technology areas
22.3
Avg claims per patent
+891%
5-year filing velocity

The verdict

Guardant holds 120 US patents across 12 technology areas, rank #3,132 of 50,000 tracked assignees.

#3,132
of 50,000 US assignees by volume
Top 8%
by Innovation Score (53.8/100)
22.3
avg claims per patent
+891%
filing velocity, last 5 yrs

Portfolio overview

Guardant Health, Inc. has been granted 120 US utility patents between 2017 and 2025, placing Guardant Health, Inc. at rank #3,132 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.3 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Guardant Health, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Guardant sits between Toshiba Lighting & Technology Corporation (121 patents, rank #3,128) and Linak A/s (120 patents, rank #3,136) - the closest US assignees by grant volume. The composite Innovation Score of 53.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 109 grants, compared with 11 in the 2015–2019 window, a +891% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Guardant Health, Inc.'s 22.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Guardant Health, Inc. against peers pursuing similar technology classes.

Who files at Guardant's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Guardant holds 120 patents at rank #3,132, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Guardant

By rank, the assignees closest to #3,132 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Guardant's primary technology class.

Guardant's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0510152025 201720182019202020212022202320242025 20
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Guardant Health, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 5 4.2%
2018 2 1.7%
2019 4 3.3%
2020 12 10.0%
2021 18 15.0%
2022 16 13.3%
2023 21 17.5%
2024 22 18.3%
2025 20 16.7%

Which technologies does Guardant Health, Inc. patent most?

Top 12 of 12 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#3,132

Across all tracked assignees

Innovation Score

53.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Guardant Health, Inc. hold?
Guardant Health, Inc. holds 120 US granted patents filed between 2017 and 2025, spanning 12 technology areas.
What is Guardant Health, Inc.'s Innovation Score?
Guardant Health, Inc. has an Innovation Score of 53.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Guardant Health, Inc. focus on?
Guardant Health, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 110 patents. The company has filed patents in 12 CPC subclasses total.
Is Guardant Health, Inc.'s patent filing rate increasing or decreasing?
Guardant Health, Inc.'s recent filing velocity is +891% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Guardant Health, Inc.'s patents?
Guardant Health, Inc.'s patents average 22.3 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Guardant Health, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Guardant's 120 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Guardant ranks #3,132 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.